Pauling Biotech Symposium Speakers MIT Faculty Club, Cambridge, MA, USA Click here to register This is a preliminary list of speakers from other institutions. More will be added soon. Other Institutions Sonia Sparks Wallman, PhD NH Biotech Council Sonia Guterman, PhD Mintz Levin Tolleiv Trimborn, PhD Life Sciences Partners VC Sunny Tam, PhD Charles River Lab Andy Bhattacharjee, PhD Agilent Dyana Dalton, PhD Trudeau Institute James Lyons-Weiler, PhD University of Pittsburgh David G. Lowe, PhD Skyline Ventures Sonia Wallman, PhD Sonia Sparks Wallman PhD, New Hampshire Biotechnology Council Dr. Wallman holds a PhD in Biology from Harvard University. Since 1994 she has been involved in biotechnology education and training. In that year she started a biotechnology technician-training program at the New Hampshire Community Technical College System's Pease International Tradeport Campus, that is modeled after an integrated biotechnology company (a Virtual Workplace). In order to set up an education and training program that models the industry, Dr. Wallman has worked with biotech companies in her state and nationally, and with agencies responsible for generating the Bioscience and Agricultural Biotechnology Skill Standards used by biotechnology educators. In 2002, Dr. Wallman was instrumental in obtaining funding for, designing, and building the new 5,000 square-foot New Hampshire Biotechnology Education and Training (NH BET) Center for Discovery Research and Biomanufacturing. The NH BET Center also functions as an incubator for small biotechnology companies. Dr. Wallman is the founder of the New Hampshire Biotechnology Council. She is a past member of the board of directors of the Council of Biotechnology Centers of the Biotechnology Industry Organization and is a member of the board of directors of the New England branch of the Society for Industrial Microbiology. In 1998, she became Northeast Region Director of Bio-Link, a National Science Foundation Advanced Technological Education (NSF ATE) Center for Biotechnology. Back to Top Sonia Guterman, PhD Sonia Guterman PhD, Patent Attorney, Mintz Levin Dr. Guteman specializes in patent prosecution in the areas of biotechnology and medicine, development of strategies for broad IP protection, and commercialization for new and emerging companies. She is a founder of Protein Engineering Corp., now Dyax, where she served as Vice President for Research, and is a co-inventor of their patents on protein remodeling with phage display. Prior to Protein Engineering, she was a Senior Scientist at BioTechnica, and inventor of a Streptomyces secretion vector. As a technology licensing officer for biotechnology at M.I.T., she negotiated over 35 deals, and has used this experience as an attorney representing both academic institutions and companies in drafting license agreements and in licensing negotiations. At M.I.T., she analyzed academic biotechnology license data and co-authored a study on the impact of licensing on the economy, and has been invited to speak on this topic at numerous conferences. Immediately prior to joining Mintz Levin, she was a patent attorney at Bromberg & Sunstein in Boston. Sonia is admitted to practice in Massachusetts and before the U.S. Patent and Trademark Office. She received a J.D. from Suffolk University (2000), a Ph.D. in microbiology from M.I.T. where she worked with Nobelist Salvador Luria, and a B.S. (biochemistry) and M.S. (genetics) from Cornell University. Prior to joining the biotechnology industry, she did postdoctoral studies with Prof. Andrew Wright at Tufts Medical School, and held a tenured professorship in genetics at Boston University where her research was supported by grants from NIH-GMS, NSF, American Heart Association, and March-of-Dimes. She is particularly proud of the students who worked in her lab at BU, some of whom can be found in positions at prominent universities and corporations. Back to Top Tolleiv Trimborn, PhD Tolleiv Trimborn PhD, Life Sciences Partners-a Venture Capital Tolleiv Trimborn holds a PhD in Molecular Biology from the Erasmus University of Rotterdam. He studied gene regulation and chromatin function in the laboratory of Prof. Frank Grosveld. He received his post-doctoral training at Stanford University in California where he worked with Prof. Roel Nusse and studied signal-transduction. Before he joined Life Sciences Partners -a Venture Capital firm - he worked at a biotech start-up in Palo Alto that focused on antibody technology. Back to Top Sunny Tam PhD, Manager for Proteomics, Charles River Lab Dr. Tam recently joined Charles River Proteomic Services as the Manager of Sample Preparation. He has worked in the drug development and technology development industry for the past 10 years. During his tenure, he held key positions in project management such as head of proteomic discovery at Texas Biotech Corporation and project leader in protein microarray development at Genometrix Inc. Dr. Tam received his B.S. from Boston College and Ph.D. from Boston University Medical Center. Furthermore, he was trained extensively as a post-doctoral fellow in Cell Biology at Harvard School of Public Health. Back to Top Andy Bhattacharjee PhD, Scientific Consultant, Agilent Dr. Andy Bhattacharjee is a Scientific Consultant and Pre-Sales System Applications Engineer at Agilent Technologies, where he has worked since 2002. Dr. Bhattacharjee holds a BSc from Banaras Hindu University, in India, an MSc from the University of Saskatchewan, in Canada, and a PhD from the University of Minnesota. His PhD research demonstrated the role of TNF-alpha in dimethylnitrosamine induced liver injury and carcinogenesis, using differential display techniques. From 1998-2002, Dr. Bhattacharjee performed postdoctoral work at the Dana-Farber Cancer Institute on Affymetrix probe array technology. There, he developed a molecular classification and class prediction methodology for human lung cancer*. Much of Dr. Bhattacharjee's work at Agilent has focused on providing scientific consultation and research expertise in the areas of genomics and array biology for customers engaged in drug discovery efforts or basic biology. He has published five original research papers, contributed two book chapters, and is an inventor on three disclosures and issued patents. * Bhattacharjee et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci 98, 13790 Back to Top Dyana Dalton PhD, Associate Professor, Trudeau Institute Dr. Dyana Dalton is an Associate Member at Trudeau Institute and serves as an adjunct Associate Professor at Albany Medical School Department of Microbiology, Immunology and Molecular Genetics. Dr. Dalton performs research at a non-profit institution that is devoted to basic immunological research. She has a unique combination of corporate and academic experience, previously holding positions as a project leader at Systemix, Inc., as a visiting scholar at Oxford University, UK, and as a post-doctoral fellow at Genentech, Inc. She holds a PhD in Genetics from Yale University. Dr. Dalton also holds a Bachelor's degree in Biochemistry and Cell Biology from the University of California, San Diego. Dr. Dalton has served on several NIH study sections to review Biodefense grant proposals and has given numerous invited seminars at scientific meetings and at universities. She has over 20 publications, including a book chapter review on the cytokine IFN-g. Her current research interests include the paradoxical roles of "pro-inflammatory" cytokines and molecules in suppressing CNS inflammation, the effect of chronic mycobacterial infection on concurrent immune responses (autoimmune diseases and responses to vaccines), and the development of live recombinantvaccines to induce enduring cellular immunity to aerosolized lung pathogens (potential bioweapons). Back to Top James Lyons-Weiler, PhD James Lyons-Weiler PhD, Assistant Professor, Department of Pathology; Core Faculty Member, Center for Biomedical Informatics, University of Pittsburgh, and Bioinformatics Shared Services/Cancer Informatics Services, University of Pittsburgh Cancer Institute Dr. Lyons-Weiler, a recipient of an Alfred P. Sloan Postdoctoral Fellowship in computational molecular biology, is leading the effort at the University of Pittsburgh Cancer Institute to integrate data from high-throughput platforms with clinical and demographic data for biomarker discovery, and interpretation of expression patterns in high- and mid-throughput panels of validated biomarkers for cancer detection, prevention, progression and therapy responses.His algorithms and software have been instrumental in elucidating the likely role of genomic integration during the origin of eukaryotes (NAR 2000, 28:463), confirming a role for loss of uroguanylin function in human colorectal cancer (Appl Bioinf 2003, 2:197), and identifying genes that are differentially expressed in only a subset of patients (BMC Bioinformatics 2004, 5:110). He teaches a course ("Practical Analysis of High-Throughput Genomic and Proteomic Data") and offers an annual free workshop on microarray data analysis (apiii.upmc.edu). His online, open access and open source micoarray data analysis web application has over 3,000 repeat users (bioinformatics.upmc.edu). He is the Associate Editor of Applied Bioinformatics and Editor-in-Chief of Cancer Informatics. He is regularly invited to speak at international conferences on topics ranging from optimizing the process of discovery and validation to the sociological factors that limit discovery and translation in biomedical science. Back to Top David G. Lowe, PhD David G. Lowe PhD, Skyline Ventures David has been involved as a research scientist, managing and leading drug discovery programs, and advising and investing in life sciences companies since 1985. He is a molecular biologist and was Director of Cardiovascular Research at Genentech, Inc., (NYSE:DNA) where he worked for 16 years. At Genentech, David led drug discovery activities in biologics and small molecule therapeutics. He was responsible for drug discovery efforts that resulted in eight drug candidates taken into clinical development, including the successful cancer therapy Avastin™. David was a member of the therapeutic area team responsible for cardiovascular strategic planning and product portfolio management, and worked extensively with Business Development on in-licensing of early and late-stage therapeutics, and technology access. David holds BS and PhD degrees in biochemistry from the University of Toronto, Canada. He has authored over 60 peer-reviewed scientific publications and is an inventor on 7 issued or pending US patents. He is a member of the Advisory Board of the Institute of Molecular Medicine at the University of California, San Diego. He joined Skyline in 2002. Back to Top Back to Speaker List See other speakers: Keynotes Pharmaceutical Companies Private Biotech Companies Public Cytokine Companies Public Biotech Companies New Start Up Companies Academic Institutions If you would like to be involved with the 2004 Symposium please email Dr. Grace Wong at gw@studentvision.org. Home | Mission | Registration | Sponsors | Job Strategies | News, Events, Contact Biotech Booth | Event Photos | Nobel Day | Dr. Linus Pauling | Who's Who Pauling Biotech Symposium | Symposium Agenda | Symposium Speakers | Symposium Testimonials Founder & Board of Directors | Scientific Advisory Committee | Scholarship Application copyright 2004